Neuralstem (AMEX: CUR) receives Notice of Patent Allowance
For Spinal Cord Delivery Platform
NYSE AMEX: CUR has received a notice of allowance from the US PTO for patent application #12/418,170 pertaining to a “Spinal Platform and Method for Delivering a Therapeutic Agent to a Spinal Cord Target.”
The Bottom Line:Neuralstem is the exclusive worldwide licensee of this device from the Cleveland Clinic Foundation, where it was developed by Nicholas Boulis, MD, formerly of the Cleveland Clinic, now atEmoryUniversity. CUR has a solid safety profile for this device demonstrated by the first 12 patients of the ongoing ALS trial.
Categories: Neuralstem (AMEX; CUR), Patent Issuance
